Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Silverman IM"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Anesthesia & Analgesia. 65:520
Hepar in Associated Thrombocytopenia (HAT) is a well-described clinical entity (1–5), frequently requiring prompt cessation of heparin therapy to correct the thrombocytopenia. Previously recommended management also called for discontinuing heparin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6740e8f0d2d40ebafe4ba73e00283074
https://doi.org/10.1213/00000539-198605000-00018
https://doi.org/10.1213/00000539-198605000-00018
Autor:
Fontana E; Sarah Cannon Research Institute UK, London, UK., Rosen E; Early Drug Development and Breast Medicine Services, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lee EK; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Højgaard M; Department of Oncology, Rigshospitalet, Copenhagen, Denmark., Mettu NB; Medical Oncology, Duke University, Durham, NC, USA., Lheureux S; Princess Margaret Cancer Centre, Toronto, ON, Canada., Carneiro BA; Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, Division of Hematology/Oncology, Department of Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USA., Cote GM; Mass General Cancer Center, Boston, MA, USA., Carter L; Division of Cancer Sciences, The University of Manchester, Manchester, UK.; The Christie NHS Foundation Trust, Manchester, UK., Plummer R; Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle upon Tyne, UK., Mahalingam D; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Fretland AJ; Repare Therapeutics, Cambridge, MA, USA., Schonhoft JD; Repare Therapeutics, Cambridge, MA, USA., Silverman IM; Repare Therapeutics, Cambridge, MA, USA., Wainszelbaum M; Repare Therapeutics, Cambridge, MA, USA., Xu Y; Repare Therapeutics, Cambridge, MA, USA., Ulanet D; Repare Therapeutics, Cambridge, MA, USA., Koehler M; Repare Therapeutics, Cambridge, MA, USA., Yap TA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Journal of the National Cancer Institute [J Natl Cancer Inst] 2024 Sep 01; Vol. 116 (9), pp. 1439-1449.
Autor:
Nakazawa MS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Silverman IM; Repare Therapeutics, Cambridge, Massachusetts., Rimkunas V; Repare Therapeutics, Cambridge, Massachusetts., Veloso A; Repare Therapeutics, Cambridge, Massachusetts., Glodzik D; Repare Therapeutics, Cambridge, Massachusetts., Johnson A; Repare Therapeutics, Cambridge, Massachusetts., Ohsumi TK; Repare Therapeutics, Cambridge, Massachusetts., Patel SR; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roland CL; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Soliman PT; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Beird HC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ingram DR; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lazcano R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Song D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wani KM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lazar AJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Livingston JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2024 Jul 02; Vol. 23 (7), pp. 1057-1065.
Autor:
Saleh M; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, USA; Department of Hematology and Oncology, Aga Khan University, Nairobi, Kenya. Electronic address: mansoor.saleh@aku.edu., Barve M; Mary Crowley Cancer Research Center, Dallas., Subbiah V; Sarah Cannon Research Institute, Nashville., Papadopoulos KP; START San Antonio, San Antonio., Morgensztern D; Division of Oncology, Washington University School of Medicine, St. Louis., Mettu NB; Division of Medical Oncology, Duke University Medical Center, Durham., Roychowdhury S; The Ohio State University Comprehensive Cancer Center, Columbus, USA., Spanggaard I; Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark., Veronese ML; Incyte International Biosciences Sàrl, Morges, Switzerland., Tian C; Incyte Corporation, Wilmington., Silverman IM; Incyte Corporation, Wilmington., Gutierrez M; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA.
Publikováno v:
ESMO open [ESMO Open] 2024 Jul; Vol. 9 (7), pp. 103625. Date of Electronic Publication: 2024 Jul 09.
Autor:
Pelster MS; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA. meredith.pelster@scri.com., Silverman IM; Repare Therapeutics, Cambridge, MA, USA., Schonhoft JD; Repare Therapeutics, Cambridge, MA, USA., Johnson A; Repare Therapeutics, Cambridge, MA, USA., Selenica P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ulanet D; Repare Therapeutics, Cambridge, MA, USA., Rimkunas V; Repare Therapeutics, Cambridge, MA, USA., Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Publikováno v:
NPJ precision oncology [NPJ Precis Oncol] 2024 Apr 01; Vol. 8 (1), pp. 82. Date of Electronic Publication: 2024 Apr 01.
Autor:
Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org., Fontana E; Sarah Cannon Research Institute UK, London, UK., Lee EK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Spigel DR; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Højgaard M; Department of Oncology, Rigshospitalet, Copenhagen, Denmark., Lheureux S; Princess Margaret Cancer Centre, Toronto, ON, Canada., Mettu NB; Department of Medical Oncology, Duke University, Durham, NC, USA., Carneiro BA; Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, Division of Hematology/Oncology, Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA., Carter L; Division of Cancer Sciences, University of Manchester and the Christie NHS Foundation Trust, Manchester, UK., Plummer R; Newcastle University and Newcastle Hospitals NHS Foundation Trust, Northern Centre for Cancer Care, Newcastle-upon-Tyne, UK., Cote GM; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Connell J; Repare Therapeutics, Cambridge, MA, USA., Schonhoft JD; Repare Therapeutics, Cambridge, MA, USA., Wainszelbaum M; Repare Therapeutics, Cambridge, MA, USA., Fretland AJ; Repare Therapeutics, Cambridge, MA, USA., Manley P; Repare Therapeutics, Cambridge, MA, USA., Xu Y; Repare Therapeutics, Cambridge, MA, USA., Ulanet D; Repare Therapeutics, Cambridge, MA, USA., Rimkunas V; Repare Therapeutics, Cambridge, MA, USA., Zinda M; Repare Therapeutics, Cambridge, MA, USA., Koehler M; Repare Therapeutics, Cambridge, MA, USA., Silverman IM; Repare Therapeutics, Cambridge, MA, USA., Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rosen E; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Publikováno v:
Nature medicine [Nat Med] 2023 Jun; Vol. 29 (6), pp. 1400-1411. Date of Electronic Publication: 2023 Jun 05.
Autor:
Glodzik D; Repare Therapeutics, Cambridge, Massachusetts., Selenica P; Memorial Sloan Kettering Cancer Center, New York, New York., Rogge RA; Invitae, Boulder, Colorado., Silverman IM; Repare Therapeutics, Cambridge, Massachusetts., Mandelker D; Memorial Sloan Kettering Cancer Center, New York, New York., Harris S; Invitae, Iselin, New Jersey., Zhao J; Invitae, Iselin, New Jersey., Zinda M; Repare Therapeutics, Cambridge, Massachusetts., Veloso A; Repare Therapeutics, Cambridge, Massachusetts., Malani N; Invitae, Iselin, New Jersey., Riaz N; Memorial Sloan Kettering Cancer Center, New York, New York., Koehler M; Repare Therapeutics, Cambridge, Massachusetts., Daber RD; Invitae, Iselin, New Jersey., Johnson V; Invitae, Boulder, Colorado., Rimkunas V; Repare Therapeutics, Cambridge, Massachusetts., Reis-Filho JS; Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: reisfilj@mskcc.org.
Publikováno v:
The Journal of molecular diagnostics : JMD [J Mol Diagn] 2023 May; Vol. 25 (5), pp. 295-310. Date of Electronic Publication: 2023 Mar 20.
Autor:
Murugesan K; Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA., Necchi A; Genitourinary Medical Oncology, Vita-Salute San Raffaele University, Milan; Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy., Burn TC; Translational and Data Sciences, Incyte Corporation, Wilmington., Gjoerup O; Scientific and Medical Publications, Foundation Medicine, Inc., Cambridge, USA., Greenstein R; Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA., Krook M; Research Scientist, Ohio State University, Columbus, USA., López JA; Integrated Healthcare Solutions, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Montesion M; Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA., Nimeiri H; Global Clinical Development Lead Oncology, Foundation Medicine, Inc., Cambridge, USA., Parikh AR; Oncology (Medical/Hematology), Jefferson Health, Philadelphia, USA., Roychowdhury S; Medical Oncology, Ohio State University, Columbus, USA., Schwemmers S; Integrated HealthCare Solutions PDMA (Oncology), F. Hoffmann-La Roche Ltd, Basel, Switzerland., Silverman IM; Clinical Bioinformatics, Incyte Corporation, Wilmington., Vogel A; Clinic for Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, Hannover, Germany. Electronic address: Vogel.Arndt@mh-hannover.de.
Publikováno v:
ESMO open [ESMO Open] 2022 Dec; Vol. 7 (6), pp. 100641. Date of Electronic Publication: 2022 Nov 30.
Autor:
Zingg D; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Bhin J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., Yemelyanenko J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Kas SM; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Rolfs F; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Lutz C; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Lee JK; Foundation Medicine, Cambridge, MA, USA., Klarenbeek S; Experimental Animal Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Silverman IM; Incyte Research Institute, Wilmington, DE, USA., Annunziato S; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Chan CS; Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA., Piersma SR; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Eijkman T; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Badoux M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Gogola E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Siteur B; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sprengers J; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Klein B; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Goeij-de Haas RR; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Riedlinger GM; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA.; Department of Pathology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Ke H; Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA., Madison R; Foundation Medicine, Cambridge, MA, USA., Drenth AP; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., van der Burg E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Schut E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Henneman L; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Miltenburg MH; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Proost N; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands., Zhen H; Incyte, Wilmington, DE, USA., Wientjens E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Bruijn R; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Ruiter JR; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boon U; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., de Korte-Grimmerink R; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Gerwen B; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands., Féliz L; Incyte Biosciences International, Morges, Switzerland., Abou-Alfa GK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA., Ross JS; Foundation Medicine, Cambridge, MA, USA.; Upstate University Hospital, Upstate Medical University, Syracuse, NY, USA., van de Ven M; Mouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands., Rottenberg S; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.; Bern Center for Precision Medicine, University of Bern, Bern, Switzerland., Cuppen E; Oncode Institute, Utrecht, The Netherlands.; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands., Chessex AV; Debiopharm International, Lausanne, Switzerland., Ali SM; Foundation Medicine, Cambridge, MA, USA., Burn TC; Incyte Research Institute, Wilmington, DE, USA., Jimenez CR; OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Ganesan S; Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. ganesash@cinj.rutgers.edu.; Department of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA. ganesash@cinj.rutgers.edu., Wessels LFA; Oncode Institute, Utrecht, The Netherlands. l.wessels@nki.nl.; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands. l.wessels@nki.nl., Jonkers J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl.; Oncode Institute, Utrecht, The Netherlands. j.jonkers@nki.nl.
Publikováno v:
Nature [Nature] 2022 Sep; Vol. 609 (7929), pp. E13.